Buh-bye Bitcoin?

Apart from their utility in criminal finances, Bitcoin and other cryptocurrencies (other than stablecoin) are manifestations of The Greater Fool Theory of Investing. So how is the Bitcoin investment performing for ya?

“The world’s largest cryptocurrency slipped below $76,000 in thin weekend trading, dropping about 40% from its 2025 peak and revisiting levels last seen in the aftermath of the “Liberation Day” tariff fallout.”

*snip*

“Bitcoin fell nearly 11% in January, marking its fourth straight monthly decline — the longest losing streak since 2018, during the crash that followed the 2017 boom in initial coin offerings.

“I don’t think we’ll see a new all-time high for Bitcoin in 2026,” said Paul Howard, director at market maker Wincent.”

So a buying opportunity, right?

“Even more striking than the drop itself is the relative lack of optimism around it on social media. In a space known for relentless bravado and “number go up” memes, Bitcoin’s slide has been met with little cheerleading or dip-buying fanfare.”

Is Bitcoin dead? Of course not. As long as there is organized crime, there will be a demand for cryptocurrency. But it’s not an investment, it’s gambling. Fool, money, parted, etc.

https://finance.yahoo.com/news/bitcoin-break-below-80-000-061355911.html

Comments

Post a Comment

Popular posts from this blog

Yes, the CDC can change its mind

The Nobel Laureate economist Paul Samuelson famously acknowledged in a Meet the Press interview: “Well when events change, I change my mind. What do you do?” This observation applies to the advice from medical authorities such as the CDC and WHO during the COVID pandemic. Some members of the public are fond of pillorying these agencies for having published different guidelines at different times, as though health officials are in the business of issuing ex cathedra dogma rather than responding to incomplete and ambiguous information. Science doesn’t deal in proof, it deals with the weight of evidence. A scientific hypothesis is one that is capable of being tested and falsified by experiment. I get it. I used to teach problem-based learning to first year medical students, and they often struggled with what to do with incomplete and ambiguous information, which is what physicians in clinics do every day. Sometimes, one cannot wait for all the tests to be completed and all the data analyz...
Read more

About that Trump lawsuit

So Trump is suing Rupert Murdoch for defamation because of the release of a salacious doodle. Nothing remarkable about Donald J. Trump weaponizing the legal system against his opponents, I know. But there are some things that do bear remark here: “ . . . he's suing Rupert Murdoch personally. But you know who he's not suing? Lachlan Murdoch, who's actually the chairperson of News Corp and Fox, who's actually the decision-maker. Rupert Murdoch has no official role there anymore. He's an adviser.   “So, I thought that was revealing in a lot of ways, because it isn't just about going after the entity. It's sort of this expansion spillover, trying to send as much of a message as you possibly can. He's sort of hitting every potential lever, not just against Murdoch and that empire, but then all the other media properties in the future. It's also about sending an example.” “HAYES: Yeah. That, to me, is the point here, is that these lawsuits are not lawsuits...
Read more

I agree with RFK Jr.

Though it feels weird to say it, RFK Jr and I agree on something: curtailing direct-to-consumer marketing of pharmaceuticals. “ The Trump administration is discussing policies that would make it harder and more expensive for pharmaceutical companies to advertise directly to patients, in a move that could disrupt more than $10 billion in annual ad spending.   Although the US is the only place, besides New Zealand, where pharma companies can directly advertise, banning pharma ads outright could make the administration vulnerable to lawsuits, so it’s instead focusing on cutting down on the practice by adding legal and financial hurdles, according to people familiar with the plans who weren’t authorized to speak publicly on the matter.   “The two policies the administration has focused in on would be to require greater disclosures of side effects of a drug within each ad — likely making broadcast ads much longer and prohibitively expensive — or removing the industry’s ability to d...
Read more